1. Home
  2. GSBD vs MNKD Comparison

GSBD vs MNKD Comparison

Compare GSBD & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSBD
  • MNKD
  • Stock Information
  • Founded
  • GSBD 2012
  • MNKD 1991
  • Country
  • GSBD United States
  • MNKD United States
  • Employees
  • GSBD N/A
  • MNKD N/A
  • Industry
  • GSBD Finance: Consumer Services
  • MNKD Biotechnology: Pharmaceutical Preparations
  • Sector
  • GSBD Finance
  • MNKD Health Care
  • Exchange
  • GSBD Nasdaq
  • MNKD Nasdaq
  • Market Cap
  • GSBD 1.4B
  • MNKD 1.4B
  • IPO Year
  • GSBD N/A
  • MNKD 2004
  • Fundamental
  • Price
  • GSBD $10.65
  • MNKD $4.63
  • Analyst Decision
  • GSBD Sell
  • MNKD Buy
  • Analyst Count
  • GSBD 2
  • MNKD 6
  • Target Price
  • GSBD $12.00
  • MNKD $8.92
  • AVG Volume (30 Days)
  • GSBD 730.0K
  • MNKD 1.6M
  • Earning Date
  • GSBD 05-08-2025
  • MNKD 05-08-2025
  • Dividend Yield
  • GSBD 18.06%
  • MNKD N/A
  • EPS Growth
  • GSBD N/A
  • MNKD 215.86
  • EPS
  • GSBD 0.55
  • MNKD 0.10
  • Revenue
  • GSBD $434,374,000.00
  • MNKD $297,595,000.00
  • Revenue This Year
  • GSBD N/A
  • MNKD $14.23
  • Revenue Next Year
  • GSBD N/A
  • MNKD $14.56
  • P/E Ratio
  • GSBD $19.06
  • MNKD $46.60
  • Revenue Growth
  • GSBD N/A
  • MNKD 32.50
  • 52 Week Low
  • GSBD $9.51
  • MNKD $4.17
  • 52 Week High
  • GSBD $15.94
  • MNKD $7.63
  • Technical
  • Relative Strength Index (RSI)
  • GSBD 45.94
  • MNKD 41.14
  • Support Level
  • GSBD $10.42
  • MNKD $4.87
  • Resistance Level
  • GSBD $10.60
  • MNKD $5.05
  • Average True Range (ATR)
  • GSBD 0.22
  • MNKD 0.18
  • MACD
  • GSBD 0.06
  • MNKD 0.02
  • Stochastic Oscillator
  • GSBD 51.85
  • MNKD 32.86

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company's origination strategy focuses on leading the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Share on Social Networks: